Welcome to our dedicated page for Born SEC filings (Ticker: BRRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Born's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Born's regulatory disclosures and financial reporting.
Bryn Inc. reports unaudited results for the three months ended March 31, 2026, as a non-operating shell company. The Company generated no revenue and recorded a net loss of $30,937, up from $16,410 a year earlier, driven entirely by administrative expenses.
At March 31, 2026 Bryn showed a working capital deficit of $34,264 and an accumulated deficit of $117,593,073, and its auditors highlight substantial doubt about its ability to continue as a going concern. Related parties provided $24,470 of interest-free demand loans, and $93,285 of related-party debt was settled through issuing 30,015,577 common shares, bringing total common shares outstanding to 450,000,000.
Control effectively shifted on April 24, 2026 when MEDO Healthcare LLC purchased 10,000,000 super-voting Series A-1 preferred shares for $175,000 and installed new leadership. The new owners plan to rebrand as MEDO Technologies, Inc. and pursue acquisitions of nationwide pharmaceutical distributors augmented by AI-based optimization, but this strategy remains at the planning stage.
Bryn Inc. reports a change in control and new leadership. On April 24, 2026, MEDO Healthcare LLC bought 10 million shares of Bryn’s Series A-1 Preferred Stock from Custodian Ventures LLC for $175,000 in cash. Each preferred share carries the voting power of 250 common shares, so this block represents the voting power of 2.5 billion common shares.
Bryn has 450 million common shares and 10 million Series A-1 Preferred shares outstanding, giving MEDO Healthcare about 84.7% of the company’s voting power. As part of the transaction, David Lazar resigned as sole officer and director. He appointed John Leo as sole director and CEO and Arthur Magee as CFO and Secretary, bringing extensive investment banking and capital markets experience to the company’s management team.
Byrn Inc. reports 2025 results as a dormant shell with no revenue and ongoing losses. The company generated $0 revenue and recorded a net loss of $40,025, similar to the prior year. Operating expenses were limited to related-party administrative costs, and cash needs were fully met through interest-free loans from its court-appointed custodian.
Byrn ended 2025 with total assets of $0, current liabilities of $96,612, and a stockholders’ deficit of $96,612, prompting the auditor to highlight substantial doubt about its ability to continue as a going concern. As of December 31, 2025, 419,984,423 common shares and 10,000,000 super-voting Series A preferred shares were outstanding. Management states the company has no operations and is seeking a reverse merger or similar transaction to acquire an operating business.
Byrn Inc. (BRRN) filed its quarterly report for the period ended September 30, 2025, reporting no revenue and a net loss of $3,700 for the quarter and $28,582 for the nine months. The company states there is substantial doubt about its ability to continue as a going concern due to limited cash resources and ongoing losses.
Operations are inactive while management explores a potential reverse merger or similar transaction. Funding during the period came from interest‑free demand loans from a related party, with amounts due of $82,635 as of September 30, 2025. The company reported a working capital deficit of $85,168 and total liabilities of $85,168.
Management concluded that disclosure controls and internal control over financial reporting were not effective due to material weaknesses, including lack of segregation of duties and absence of an independent board or audit committee. Shares outstanding were 419,984,423 as of October 21, 2025.